<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>27(1)</volume><submitter>Li Q</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>Clinical response to the atypical antipsychotic paliperidone is known to vary among schizophrenic patients. We carried out a genome-wide association study to identify common genetic variants predictive of paliperidone efficacy.&lt;h4>Methods&lt;/h4>We leveraged a collection of 1390 samples from individuals of European ancestry enrolled in 12 clinical studies investigating the efficacy of the extended-release tablet paliperidone ER (n1=490) and the once-monthly injection paliperidone palmitate (n2=550 and n3=350). We carried out a genome-wide association study using a general linear model (GLM) analysis on three separate cohorts, followed by meta-analysis and using a mixed linear model analysis on all samples. The variations in response explained by each single nucleotide polymo</pubmed_abstract><journal>Pharmacogenetics and genomics</journal><pagination>7-18</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5152628</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Genome-wide association study of paliperidone efficacy.</pubmed_title><pmcid>PMC5152628</pmcid><pubmed_authors>Savitz A</pubmed_authors><pubmed_authors>Schork NJ</pubmed_authors><pubmed_authors>Fu DJ</pubmed_authors><pubmed_authors>Alphs L</pubmed_authors><pubmed_authors>Cohen N</pubmed_authors><pubmed_authors>Libiger O</pubmed_authors><pubmed_authors>Li Q</pubmed_authors><pubmed_authors>Gopal S</pubmed_authors><pubmed_authors>Wineinger NE</pubmed_authors></additional><is_claimable>false</is_claimable><name>Genome-wide association study of paliperidone efficacy.</name><description>&lt;h4>Objective&lt;/h4>Clinical response to the atypical antipsychotic paliperidone is known to vary among schizophrenic patients. We carried out a genome-wide association study to identify common genetic variants predictive of paliperidone efficacy.&lt;h4>Methods&lt;/h4>We leveraged a collection of 1390 samples from individuals of European ancestry enrolled in 12 clinical studies investigating the efficacy of the extended-release tablet paliperidone ER (n1=490) and the once-monthly injection paliperidone palmitate (n2=550 and n3=350). We carried out a genome-wide association study using a general linear model (GLM) analysis on three separate cohorts, followed by meta-analysis and using a mixed linear model analysis on all samples. The variations in response explained by each single nucleotide polymo</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Jan</publication><modification>2026-04-13T08:03:42.886Z</modification><creation>2026-04-07T13:29:19.951Z</creation></dates><accession>S-EPMC5152628</accession><cross_references><pubmed>27846195</pubmed><doi>10.1097/FPC.0000000000000250</doi></cross_references></HashMap>